Diseases, Conditions, Syndromes

AstraZeneca: US data shows vaccine effective for all adults

AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study, a finding that could help rebuild public confidence in the shot around the world ...

Diseases, Conditions, Syndromes

Major COVID-19 vaccine trial resumes in UK after safety review

Pharma giant AstraZeneca and Oxford University on Saturday said they had resumed a COVID-19 vaccine trial after getting the all-clear from British regulators, following a pause caused by a UK volunteer falling ill.

Diabetes

A step closer to a cure for adult-onset diabetes

In healthy people, exosomes – tiny structures secreted by cells to allow intercellular communication – prevent clumping of the protein that leads to type 2 diabetes. Exosomes in patients with the disease don't have the ...

Oncology & Cancer

Faulty gene connected to ovarian cancer risk

In a new study published in Nature Genetics researchers say that women who possess a fault in a gene named RAD51D have a greater risk of developing ovarian cancer than women who do not have this fault and tests are expected ...

Vaccination

EMA official suggests ditching AstraZeneca jab

A top official in the European Medicines Agency said it might be worth abandoning AstraZeneca's coronavirus vaccine for all age groups where alternatives are available, in an interview published Sunday.

page 1 from 29

AstraZeneca

AstraZeneca plc (LSE: AZN, OMX: AZN, NYSE: AZN), is a large Anglo-Swedish pharmaceutical company formed on 6 April 1999 by the remerger of Swedish Astra AB and British Zeneca Group plc. Zeneca had been part of Imperial Chemical Industries, as 3 divisions that were spun off from ICI on 1 June 1993. The Company is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.

This text uses material from Wikipedia, licensed under CC BY-SA